Human pancreatic cancer cells (MPanc-96) recognized by autologus tumor-infiltrating lymphocytes after in vitro as well in vivo tumor expansion

International Journal of Cancer

Volumn 71, Issue 6, 1997, Pages 993-999

  Peiper, Matthias ^a,b   Nagoshi, Makoto ^a   Patel, Dipak ^a   Fletcher, Jonathan A ^a   Goegebuure, Peter S ^a   Eberlein, Timothy J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SCID MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

EID: 0030967252     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970611)71:6<993::AID-IJC15>3.0.CO;2-7     Document Type: Article

References (21)

1. ALEXANDER, R.B. and ROSENBERG, S.A., Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. J. Immunother., 10, 389-397 (1991).
2. BERD, D., MAGUIRE, H.C.J., MCCUE, P. and MASTRANGELO, M.J., Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. clin. Oncol., 8, 1858-1867 (1990).
3. 8+ T cells by tumor-infiltrating lymphocytes and lecombinant IL-2 during adoptive immunotherapy of cancer. Surgery, 117, 325-333 (1995).
4. FLETCHER, J.A., KOZAKEWICH, H.P., HOFFER, F.A., LAGE, J.M., WEIDNER, N., TEPPER, R., PINKUS, G.S., MORTON, C.C. and CORSON, J.M., Diagnostic relevance of clonal cytogenetic abberrations in malignant soft-tissue tumors. New Engl. J. Med., 324, 436-442 (1991).
5. GOEDEGEBUURE, P.S., DOUVILLE, L.M., LI, H., RICHMOND, G.C., SCHOOF, D.D., SCAVONA, M. and EBERLEIN, T.J., Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. clin. Oncol., 13, 1939-1949 (1995).
6. JANES, R.H., NIEDERHUBER, J.E., CHMIEL, J.S., WINCHESTER, D.P., OCWIEJA, K.C., KARNELL, L.H., CLIVE, R.E. and MENCK, H.R., National patterns of care for pancreatic cancer. Ann. Surg., 223, 261-212 (1996).
7. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K. and ROSENBERG, S.A., Identification of the imniunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
8. LINEHAN, D.C., GOEDEGEBUURE, P.S. and EBERLEIN, T.J., Vaccine therapy for cancer. Ann. Surg. Oncol., 3, 219-229 (1996).
9. MARCHAND, M. and 20 OTHERS. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, 883-885 (1995)
10. MARINCOLA, F.M., SIAO, D.Y., DRUCKER, B.J, and HOLDER, W.D., Lymphokine-activated killer cell activity in patients with cancer of the pancreas. Current Surg., 45, 298-301 (1988).
11. PEIPER, M., LINEHAN, D.C., GANGULY, E., DOUVILLE, C., GOEDEGEBUURE, P.S. and EBERLEIN, T.J., Lysis of pancreatic cancer cells by tumor-specific T-cells is associated with tumor cell-expression of HER2/neu. Surg. Forum, 46, 140-142 (1995).
12. PEOPLES, G.E., GOEDEGEBUURE, P.S., SMITH, R., LINEMAN, D.C., YOSHINO, I. and EBERLEIN, T.J., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. nat. Acad. Sci. (Wash.), 92, 432-436 (1995).
13. PEOPLES, G.E., SCHOOF, D.D., ANDREWS, V.R., GOEDEGEBUURE, P.S. and EBERLEIN, T.J., T-cell recognition of ovarian cancer. Surgery, 114, 227-234 (1993).
14. RAVAUD, A., LEGRAND, E., DELAUNEY, M.M., BUSSIÉRES, E., COULON, V., CANY, L., HUET, S., VERDIER, D., KIND, M. and CHOMY, F., A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Brit. J. Cancer, 71, 331-336 (1995).
15. ROSENBERG, S.A., Immunotherapy of patients with melanoma antigen based on the genes encoding melanoma antigen. Proc. Amer. Assoc. Cancer Res., 37, 642-643 (1996).
16. STORKUS, W.J., ZEH III, H.J., MAEURER, M.J., SALTER, R.D. and LOTZE, M.T., Identification of human melanoma peptides recognized by class I-restricted tumor infiltrating lymphocytes. J. Immunol., 151, 3719-3727 (1993).
17. VAN DER BRUGGEN, P., SZIKORA, J.P. and BOEL, P., Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw1601. Europ. J. Immunol., 24, 2134-2140 (1994)
18. VILA, M.R., LLORETA, J., SCHUESSLER, M.H., BERROZPE, G., WELT, S. and REAL, F.X., New pancreas cancer cell lines that represent distinct stages of ductal differentiation. Lab. Invest., 72, 395-404 (1995).
19. WAHAB, Z.A. and METZGAR, R.S., Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. Pancreas, 6, 307-317 (1993).
20. WÖLFEL, T., HERR, W., COULIE, P., SCHMITT, U., MEYER ZUM BÜSCHENFELDE, K.-H. and KNUTH, A., Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int. J. Cancer, 54, 636-644 (1993).
21. YOSHINO, I., GOEDEGEBUURE, P.S., PEOPLES, G.E., PARIKH, A.S., DIMAIO, J.M., LYERLY, H.K., GAZDAR, A.F. and EBERLEIN, T.J., HER2/neu-derived peptides are shared antigens among human non small cell lung cancer and ovarian cancer. Cancer Res., 54, 3387-3390 (1994).